1/1
5 files

Efficacy of second-line ICI combined with TKI among patients with metastatic renal cell carcinoma: a real-world study. Supplementary data

dataset
posted on 21.02.2022, 11:33 by Pengfei Shen, Hao Zeng, Zhenhua Liu, Qiang Wei, Xiang Li, Jiyan Liu, Yali Shen, Yuntian Chen, Jiayu Liang, Guangxi Sun, Zilin Wang, Xudong Zhu, Xingming Zhang, Junru Chen, Haoran Zhang

Supplementary Figure 1. Kaplan-Meier curves for patients with ccRCC or non-ccRCC features. A (PFS2) and B (OS) represented survival outcomes of patents with ccRCC feature; C (PFS2) and D (OS) represented the survival outcomes of patients with non-ccRCC feature.

Supplementary Figure 2. Kaplan-Meier curves for patients with second-line ICI plus TKI treatment (n = 52) in different IMDC risk groups. A (PFS2) and B (OS) represented survival outcomes of patents in IMDC favorable-, intermediate-, and poor-risk groups; C (PFS2) and D (OS) represented the survival outcomes of patients in the intermediate-risk group; E (PFS2) and F (OS) represented the survival outcomes of patients with different number of risk factors; G (PFS2) and H (OS) represented the comparasion of survival outcomes of patients with 0-1 and ≥2 risk factors.

Supplementary Table 1. Univariate analysis of PFS and OS in mRCC patients (n = 110).

Supplementary Table 2. Correlations of genomic mutations with survival outcome in mRCC patients with ICI plus TKI treatment (n = 52)

Supplementary Table 3. Univariate analysis of PFS2 and OS in mRCC patients with ICI plus TKI treatment (n = 52)

History